WO2002078616A3 - Methods for increasing serotonin levels by administering (-)-hydroxycitric acid - Google Patents

Methods for increasing serotonin levels by administering (-)-hydroxycitric acid Download PDF

Info

Publication number
WO2002078616A3
WO2002078616A3 PCT/US2002/010368 US0210368W WO02078616A3 WO 2002078616 A3 WO2002078616 A3 WO 2002078616A3 US 0210368 W US0210368 W US 0210368W WO 02078616 A3 WO02078616 A3 WO 02078616A3
Authority
WO
WIPO (PCT)
Prior art keywords
person
administering
serotonin levels
methods
hydroxycitric acid
Prior art date
Application number
PCT/US2002/010368
Other languages
French (fr)
Other versions
WO2002078616A2 (en
Inventor
Sunny E Ohia
Harry G Preuss
Debasis Bagchi
Original Assignee
Interhealth Nutraceuticals Inc
Sunny E Ohia
Harry G Preuss
Debasis Bagchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002576884A priority Critical patent/JP2004526738A/en
Priority to NZ528681A priority patent/NZ528681A/en
Priority to EP02733934A priority patent/EP1379261A4/en
Priority to MXPA03008939A priority patent/MXPA03008939A/en
Priority to CA002442370A priority patent/CA2442370A1/en
Priority to IL15817202A priority patent/IL158172A0/en
Application filed by Interhealth Nutraceuticals Inc, Sunny E Ohia, Harry G Preuss, Debasis Bagchi filed Critical Interhealth Nutraceuticals Inc
Priority to AU2002305132A priority patent/AU2002305132B2/en
Priority to US10/473,557 priority patent/US20040157929A1/en
Publication of WO2002078616A2 publication Critical patent/WO2002078616A2/en
Publication of WO2002078616A3 publication Critical patent/WO2002078616A3/en
Priority to ZA2003/07594A priority patent/ZA200307594B/en
Priority to US12/033,419 priority patent/US20080139657A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

A method for increasing serotonin levels in a person includes identifying a person having a deficient serotonin level and administering to the person a composition incorporating hydroxycitric acid, preferably in the form of an extract of Garcinia cambogia, in an amount sufficient to increase the person's serotonin levels. The method also can incorporate administering chromium, preferably in the form of oxygen-coordinated, niacin-bound chromium, and gymnemic acid, preferably in the form of an extract of Gymnema sylvestre, to synergistically work to further increase serotonin levels in the person.
PCT/US2002/010368 2001-03-30 2002-04-01 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid WO2002078616A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NZ528681A NZ528681A (en) 2001-03-30 2002-04-01 Compositions comprising (-)-hydroxycitric acid (HCA), chromium and gymnemic acid to increase serotonin levels and induce weight loss
EP02733934A EP1379261A4 (en) 2001-03-30 2002-04-01 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
MXPA03008939A MXPA03008939A (en) 2001-03-30 2002-04-01 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof.
CA002442370A CA2442370A1 (en) 2001-03-30 2002-04-01 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
IL15817202A IL158172A0 (en) 2001-03-30 2002-04-01 Pharmaceutical compositions containing (-)-hydroxycitric acid
JP2002576884A JP2004526738A (en) 2001-03-30 2002-04-01 A method for increasing human serotonin levels by administering a composition containing hydroxycitric acid and related compositions thereof
AU2002305132A AU2002305132B2 (en) 2001-03-30 2002-04-01 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
US10/473,557 US20040157929A1 (en) 2002-04-01 2002-04-01 Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
ZA2003/07594A ZA200307594B (en) 2001-03-30 2003-09-30 Method for increasing serotonin levels in a person by administration of a composition incorporating hydroxycitric acid and related compositions thereof
US12/033,419 US20080139657A1 (en) 2001-03-30 2008-02-19 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28059301P 2001-03-30 2001-03-30
US60/280,593 2001-03-30
US34347301P 2001-12-20 2001-12-20
US60/343,473 2001-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/033,419 Division US20080139657A1 (en) 2001-03-30 2008-02-19 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof

Publications (2)

Publication Number Publication Date
WO2002078616A2 WO2002078616A2 (en) 2002-10-10
WO2002078616A3 true WO2002078616A3 (en) 2002-11-28

Family

ID=26960381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010368 WO2002078616A2 (en) 2001-03-30 2002-04-01 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid

Country Status (9)

Country Link
EP (1) EP1379261A4 (en)
JP (1) JP2004526738A (en)
AU (1) AU2002305132B2 (en)
CA (1) CA2442370A1 (en)
IL (1) IL158172A0 (en)
MX (1) MXPA03008939A (en)
NZ (1) NZ528681A (en)
WO (1) WO2002078616A2 (en)
ZA (1) ZA200307594B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927636B1 (en) 1997-07-14 2011-04-19 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US7119110B2 (en) 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US8394856B2 (en) * 2002-07-02 2013-03-12 Glykon Technologies Group, Llc (-)-Hydroxycitric acid for controlling inflammation
US20040186181A1 (en) * 2003-03-21 2004-09-23 Interhealth Nutraceuticals, Incorporated Method and composition for decreasing ghrelin levels
US20050215644A1 (en) * 2004-03-19 2005-09-29 Interhealth Nutraceuticals, Inc. Methods for increasing neurotransmitter levels using hydroxycitric acid
US20210369656A1 (en) * 2020-06-02 2021-12-02 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for elevating ketone utilization
EP4157199A1 (en) 2020-06-02 2023-04-05 Glykon Technologies Group, LLC Methods and pharmaceutical preparations for elevating blood hemoglobin and oxygen saturation levels with hydroxycitric acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US6217898B1 (en) * 1995-12-15 2001-04-17 Sigma-Tau Healthscience S.P.A. Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217898B1 (en) * 1995-12-15 2001-04-17 Sigma-Tau Healthscience S.P.A. Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid

Also Published As

Publication number Publication date
ZA200307594B (en) 2005-05-25
CA2442370A1 (en) 2002-10-10
EP1379261A4 (en) 2004-09-08
NZ528681A (en) 2005-03-24
JP2004526738A (en) 2004-09-02
AU2002305132B2 (en) 2007-05-31
WO2002078616A2 (en) 2002-10-10
MXPA03008939A (en) 2005-03-07
IL158172A0 (en) 2004-03-28
EP1379261A2 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
WO2004100968A3 (en) A synergistic composition for the treatment of diabetes mellitus
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
PT1158973E (en) USE OF SULFAMATE DERIVATIVES FOR THE TREATMENT OF DRIVE CONTROL DISTURBLES
WO2003051380A3 (en) Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
EP1400529A4 (en) Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
EP2255806A3 (en) Fentanyl composition for nasal administration
EP2272354A3 (en) Herbicides based on substituted thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)ones and diflufenican
DK2041133T3 (en) Derivatives of imadazole [1,2-A] pyridine-2-carboxamides, their preparation and their use in therapeutics
CA2311356A1 (en) Method for treating alzheimer's disease
WO2002078616A3 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
WO2002005642A3 (en) Synergistic biocidal compositions
BR0001201A (en) (Poly) thiaalkinoic compound, cosmetic composition, use of a cosmetic composition, use of a compound and pharmaceutical composition
WO2004085462A3 (en) Method and composition for decreasing ghrelin levels
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
WO2006047556A3 (en) Methods for making and using synergistic multifunctional compositions
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2442370

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002576884

Country of ref document: JP

WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: PA/a/2003/008939

Ref document number: 158172

Country of ref document: IL

Ref document number: 2003/07594

Country of ref document: ZA

Ref document number: 200307594

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002305132

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002733934

Country of ref document: EP

Ref document number: 528681

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002733934

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10473557

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 528681

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 528681

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002733934

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002305132

Country of ref document: AU